Pharmacological targeting of SLC25A1 and ACLY sensitizes cancer cells to ferroptosis and inhibits tumor growth both in vitro and in vivo (Fig. 7G), suggesting that an in-depth study of this pathway may provide a new strategy for ferroptosis-targeted cancer treatment. Here, SLC25A1 is linked to neoplasm.